Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

The FDA approves new antifungal oteseconazole

by Michael McCoy
May 6, 2022 | A version of this story appeared in Volume 100, Issue 16

The structure of oteseconazole

The US Food and Drug Administration has approved Vivjoa (oteseconazole), Mycovia Pharmaceuticals’ azole antifungal for chronic vaginal yeast infection. The firm says the drug is the only FDA-approved medication for the condition. Oteseconazole, a tetrazole, was designed to inhibit fungal CYP51 enzyme but not human CYP enzymes. Human enzyme inhibition accounts for the side effects of other azole antifungals on the market, Mycovia says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.